Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Chairman Positions Sinopharm As Pharmaceutical Platform Of State-Owned Enterprises

This article was originally published in PharmAsia News

Executive Summary

State-owned Assets Supervision and Administration Commission of the State Council recently appointed Song Zhiping, present chairman of the China National Building Material Group, as external director and chairman of Sinopharm. The move is regarded as a hallmark event for SASAC to push for a "professional chairman." Song was the key person who led CNBM public, while Sinopharm Medicine Holdings is preparing for a listing in Hong Kong and looking for someone with such experience. Song has mapped out the strategic direction for Sinopharm - the company will adhere to its main business while leveraging on market capital. This will help accelerate industry resources integration to forge a globally competitive pharmaceutical platform for state-owned enterprises. (Click here for more - Chinese Language)
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC072047

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel